The modular manufacturing system will anchor Sub-Saharan Africa’s first facility for advanced biologics development and production.

Kigali, Rwanda and San Francisco, USA – 3 January 2026 — Bio Usawa announced today that BioMod™, the company’s first proprietary modular biologics manufacturing platform, has completed pre-qualification testing in California and is now en route to Rwanda for deployment. The platform will anchor Sub-Saharan Africa’s first manufacturing facility for advanced biologic therapies.

The completion of key facility acceptance studies confirms that the BioMod™ platform meets defined engineering, environmental, and operational specifications prior to shipment. Final installation, commissioning, and full validation activities will be completed in Rwanda. 

Upon arrival in Rwanda, the BioMod™ platform will serve as the foundation of Bio Usawa’s monoclonal antibody (mAb) development and production hub in the Kigali Special Economic Zone. This facility will be Bio Usawa’s first integrated site for research, process development, and GMP manufacturing on the African continent, supporting a long-term vision for regional self-sustainability and reduced dependence on imported biologics.

Bio Usawa’s initial development plan focuses on monoclonal antibody therapies for cancers, eye diseases, infectious diseases, and autoimmune disorders — therapeutic areas where access barriers remain high and demand continues to grow.

“The BioMod™ pre-qualification marks a defining moment for Bio Usawa and for the future of biologics access across the continent,” said Dr. Menghis Bairu, Co-founder, CEO and President of Bio Usawa. “By delivering proprietary, modular manufacturing capacity directly into Rwanda’s innovation ecosystem, we are enabling countries to participate fully in biologics production — not as importers, but as producers.” 

The BioMod™ modular platform is designed for rapid deployment, seamless scaling, and mAbs on demand to meet local and regional needs. Its architecture shortens supply chains, reduces dependence on long-distance importation, and reinforces supply continuity during public health emergencies. The system also enables in-region technical training and skills development aligned with global quality and regulatory expectations.

The platform was engineered and constructed in partnership with Pacific Environmental Technologies Inc. (PETI), whose experience in GMP-compliant modular manufacturing environments supported the platform’s design, fabrication, and pre-qualification. 

Dr. Richard Chin, Bio Usawa Co-founder, Board Chair, and Interim Chief Scientific Officer emphasized the importance of manufacturing rigor in enabling patient access. 

“Our R&D strategy is centered on building a next-generation antibody platform capable of addressing some of the most pressing therapeutic gaps in the region,” he said. “By integrating discovery, development, and modular manufacturing into a connected ecosystem, Bio Usawa can accelerate antibody innovation and deliver targeted therapies with a level of proximity and responsiveness that traditional models simply cannot match.”

The deployment of BioMod™ represents a shift from dependence on imported biologics toward regionally anchored production built to global standards. Bio Usawa’s approach is intended to shorten supply chains, improve reliability, and expand access to high-quality, affordable treatments for patients across Africa and other underserved regions.

About Bio Usawa Inc.

Bio Usawa Biotechnology is a global health innovation company dedicated to advancing equitable access to biologic medicines through modular manufacturing technologies. By enabling nations to produce their own monoclonal antibodies and other advanced therapies, Bio Usawa is helping build resilient, sustainable, and locally empowered biotechnology ecosystems. For more information, visit www.biousawa.com.